Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials
Clear filter
647 clinical trials found
Clinical trials

Ladera

Evaluation of the Safety and Performance of the Ladera Medical Suture-Mediated Large Bore Closure [LBC] System - The Ladera LBC Feasibility Study (NCT06358157)

No longer recruiting

LASER

Treatment of Locally Advanced NSCLC with Stereotactic ablativE Radiotherapy (LASER) (ACTRN12619001186145)

Currently recruiting

Lavender D346BC00001

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults with Chronic and/or Subacute Cutaneous Lupus Erythematosus who are Refractory and/or Intolerant to Antimalarial Therapy (NCT06015737)

The D346BC00001 study is designed to evaluate the efficacy and safety of anifrolumab in adults with chronic and/or subacute lupus erythematous. 
Participants receive either trial medication or a placebo (something that looks like the trial drug but has no effect on the body), both administered weekly as injections into the skin (subcutaneous injections). The treatment period will be approximately 52 weeks with all participants moving to active treatment (receiving treatment drug) after Week 24.
 

Currently recruiting

LBS-007-CT01

A Phase 1/2, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of LBS-007 in Patients with Relapsed or Resistant Acute Leukaemias (NCT05756322)

Currently recruiting

LIBRETTO-531

A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing LOXO-292 to Physicians Choice of Cabozantinib or Vandetanib in Patients with Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531) (NCT04211337)

No longer recruiting

Librexia Study

A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack (NCT05702034)

Currently recruiting

LIGHTRAY

A Phase 2, Multicenter, Single-blinded, Randomized Study to Evaluate the Pharmacokinetics and Safety of Sotatercept [MK-7962] Administered Using Either a Weight-based or Weight-banded Approach in Participants With Pulmonary Arterial Hypertension [PAH] on Standard of Care (NCT06664801)

No longer recruiting

LIGHTRAY EXT

An Open-label Extension Study to Evaluate Safety and Tolerability of Sotatercept [MK-7962] Administered Using a Weight-banded Approach in Participants With Pulmonary Arterial Hypertension [PAH] on Standard of Care (NCT06925750)

This is an extension study, which means people who took part in MK-7962-024 (LIGHTRAY) may be able to join this study. In this extension study, people will get weight-banded doses of?sotatercept. The main goal of this study is to learn about the safety of weight-banded doses of?sotatercept?and if people tolerate it over a longer period of time.
Currently recruiting

LIVER-R

An Observational Multi center Study to Evaluate Real World Treatment Outcomes of Durvalumab based Regimens in Hepatobiliary Cancers [LIVER-R] (NCT06252753)

Currently recruiting

LM108-01-101

A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 (an Anti-CCR8 mAb) as a Single Agent or in Combination with Anti-PD-1 Antibody in Subjects with Advanced Solid Tumours (NCT05199753)

Currently recruiting

LM302

A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM302 in Combination with Toripalimab in Patients with Advanced Solid Tumors (NCT05188664)

No longer recruiting

LOLIPOP

Long-Term Outcomes of Lidocaine Infusions for Post-Operative Pain: the LOLIPOP Trial (NCT05072314)

Currently recruiting

Longboard EAP

Expanded Access Program for Treatment with LP352 for Patients with Developmental and Epileptic Encephalopathies [DEEs] (NCT06149663)

The purpose of this Expanded Access Program (EAP) is to provide continued access to LP352, an Investigational Medicinal Product (IMP), which has no marketing authorisations anywhere in the world and which is being investigated in patients with Developmental and Epileptic Encephalopathies (DEEs). Within Australia, the EAP will; allow participants of LP352-201 and LP352-202 (approved by CHQ HREC, QCH lead site) to continue to access this treatment after the participant has successfully completed the LP352-202 trial (rollover patient), or provide treatment for an immediate family member of a participant that completed the LP352-202 trial who has the exact same gene mutation resulting in the same DEE phenotype (nave participant).
Currently recruiting

Longboard LP352-302

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy, Safety, and Tolerability of LP352 in the Treatment of Seizures in Children and Adults with Dravet Syndrome (NCT06660394)

This is a global Phase 3 double-blind, randomized, Placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with Dravet syndrome. Randomisation will be stratified by 4 categories of age (2 to 5 years, 6 to 11 years, 12 to 17 years, and 18 to 65 years) and 2 categories of country region categories (Asian, not Asian). The study consists of the following periods for all participants: Screening (approximately 5 weeks), Titration (3 weeks or Days 1 to 21), and Maintenance (12 weeks or Days 22 to 105). Participants not entering the open-label extension (OLE) will complete Taper (up to 2 weeks) and Follow-up (4 weeks after completing Taper).
Currently recruiting

LONGBOARD-DB

A Phase 1b/2a randomized, double-blind, placebo-controlled, parallel-group, dose-escalation study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of LP352 in subjects with developmental and epileptic encephalopathies. (NCT05364021)

Currently recruiting

LONGBOARD-OLE

A Phase 2, multicenter, open-label, long-term safety study of LP352 in subjects with developmental and epileptic encephalopathy who completed Study LP352-201 and are candidates for continuous treatment for up to 52 weeks (NCT05626634)

Currently recruiting

Longevity LBT3627-101

A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Subjects and in Subjects with Parkinson’s disease (NCT06466525)

Currently recruiting

Low Risk TAVI

Transcatheter Aortic Valve Replacement With the Medtronic Transcatheter Aortic Valve Replacement System In Patients at Low Risk for Surgical Aortic Valve Replacement (NCT02701283)

Currently recruiting

LOXO-BTK-20020

A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator’s Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-321) (NCT04666038)

Currently recruiting

LOXO-BTK-20022

A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322) (NCT04965493)

Currently recruiting
17 18 19 20 21